You are here

WuXi Biologics

WuXi continues Western asset sale with $500M Merck deal

First Word Pharma

Mon, 01/6/25 - 10:44 am

drug manufacturing

WuXi Biologics beefs up its lobbying operation

Stat

Thu, 05/16/24 - 09:49 pm

BIOSECURE Act gets update, gives US drugmakers until 2032 to sever ties with Chinese biotechs

BioSpace

Mon, 05/13/24 - 11:27 am

BioNTech, keeping its powder dry, pays WuXi $20M for 2 preclinical monoclonal antibodies

Fierce Biotech

Thu, 01/11/24 - 11:12 am

monoclonal antibodies

WuXi Biologics bioconjugates spinout plans $470 million IPO

Biopharma Reporter

Thu, 11/9/23 - 11:30 pm

WuXi Biologics' medical research unit eyes up to $471 million in Hong Kong IPO

Reuters

Mon, 11/6/23 - 07:15 pm

Mediar gets a spark from Pfizer’s Ignite scheme as lead fibrosis programs progress

Fierce Biotech

Wed, 10/25/23 - 10:49 pm

Mediar Therapeutics

Biopharma Investment in China is Thriving Amid U.S. Downturn

BioSpace

Tue, 07/5/22 - 11:52 pm

Boehringer Ingelheim

Siemens Healthineers

WuXi stock plummets, wiping nearly $10B off market value as US adds it to ‘unverified’ list

Endpoints

Tue, 02/8/22 - 11:48 pm

Pfizer halts biosimilar programs in crowded China market, sells plant to WuXi Biologics

Fierce Pharma

Wed, 03/17/21 - 11:39 pm

Bristol Myers offloading Swiss tablet and capsule plant to Chinese CDMO WuXi STA

Fierce Pharma

Tue, 02/2/21 - 11:15 pm

Bristol-Myers Squibb

ISTA Pharmaceuticals

Looking to build a 'dual sourcing' supply chain, WuXi Biologics shells out $183M for Bayer drug substance plant

Endpoints

Mon, 12/21/20 - 11:37 pm

WuXi Biologics clinches deal to build first U.S. facility at Boston area hub

Fierce Pharma

Tue, 05/19/20 - 10:45 am